Nkarta Inc (NYSE: NKTX) — Healthcare · Share Price, Chart & Market Data
About: Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.87 (-1.88%)
NKTXNkarta Inc
Loading watchlist status…
Trade NKTX now
Nkarta Inc share price
NKTX price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 5:38 pm GMT+0
NKTX price performance
-13.705%
5D
39.078%
1M
53.209%
YTD
42.537%
1Y
NKTX price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NYSE rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 5:38 pm GMT+0
NKTX details
NKTX Market Signals